Evidence map›Paper›PMID 32706496›Full record

ArticleJournal of diabetes investigation2021

Rapid and dramatic glucose-lowering effect of bromocriptine in an inadequately controlled type 2 diabetes patient with prolactinoma.

Motoyuki Igata, Yoshitaka Yagi, Satoko Hanatani, Masaji Sakaguchi, Norio Ishii, Kayo Yoshinaga, Junji Kawashima, Hiroyuki Motoshima, Eiichi Araki

Open access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of diabetes investigation, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.4field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 8 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Motoyuki IgataDepartment of Metabolic Medicine, Faculty of Life Sciences, Kumamoto University, Kumamoto, Japan.ORCID https://orcid.org/0000-0002-7013-1562
Yoshitaka YagiDepartment of Metabolic Medicine, Faculty of Life Sciences, Kumamoto University, Kumamoto, Japan.
Satoko HanataniDepartment of Metabolic Medicine, Faculty of Life Sciences, Kumamoto University, Kumamoto, Japan.
Masaji SakaguchiDepartment of Metabolic Medicine, Faculty of Life Sciences, Kumamoto University, Kumamoto, Japan.
Norio IshiiDepartment of Metabolic Medicine, Faculty of Life Sciences, Kumamoto University, Kumamoto, Japan.
Kayo YoshinagaDepartment of Metabolic Medicine, Faculty of Life Sciences, Kumamoto University, Kumamoto, Japan.
Junji KawashimaDepartment of Metabolic Medicine, Faculty of Life Sciences, Kumamoto University, Kumamoto, Japan.
Hiroyuki MotoshimaDepartment of Metabolic Medicine, Faculty of Life Sciences, Kumamoto University, Kumamoto, Japan.
Eiichi ArakiDepartment of Metabolic Medicine, Faculty of Life Sciences, Kumamoto University, Kumamoto, Japan.ORCID https://orcid.org/0000-0002-4064-7525
Kumamoto University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Dopamine receptor agonists are typically used to treat Parkinson's disease and certain pituitary tumors, such as prolactinoma or a growth hormone-producing tumor. A 53-year-old woman with a history of prolactinoma was referred to Kumamoto University Hospital (Kumamoto, Japan) with poorly controlled type 2 diabetes. Her glycated hemoglobin and serum prolactin levels were increased (8.8% and 160.3 ng/mL, respectively). Bromocriptine, a dopamine D

Indexed as

Blood GlucoseBromocriptineDiabetes Mellitus, Type 2Dopamine AgonistsFemaleHumansMiddle AgedProlactinomaBlood GlucoseBromocriptineDopamine AgonistsBromocriptineContinuous glucose monitoringProlactinoma

Identifiers

PMID32706496
PMCPMC8015810
OpenAlexW3044942550

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.